Cerrone

Gene-Based Therapy May Slow Development of Life-Threatening Heart Condition

Retrieved on: 
Tuesday, January 30, 2024
DSM-IV codes, NYU Langone Health, Survival, Circulation, Cell, PKP2, Research, Arrhythmia, Human, Heart, Cell biology, Ischemia, Patient, Mouse, Safety, Personalized medicine, NYU, MBA, Blood, Chantal, Disease, Risk, ARVC, Doctor of Philosophy, Cardiomyopathy, Cerrone

The heart can also beat irregularly without any warning and sometimes stops working.

Key Points: 
  • The heart can also beat irregularly without any warning and sometimes stops working.
  • While current therapies can help restore the heart's normal rhythm and control symptoms, they fail to provide a cure.
  • "Our findings offer experimental evidence that gene therapy targeting plakophilin-2 can interrupt the progression of a deadly heart condition," says study co-lead author Chantal van Opbergen, PhD, a postdoctoral research fellow at NYU Langone Health.
  • According to the study authors, the most advanced stages of ARVC are marked by irreversible heart damage, sometimes requiring a heart transplant.

Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem Sciences

Retrieved on: 
Wednesday, September 16, 2020
Medical genetics, Branches of biology, Genomic Health, Companies, Musicians, Demerger, Exact Sciences, Oncotype, Cerrone, London Stock Exchange, Tiziana

Notably, Exact Sciences purchased the Oncotype DX assay from Genomic Health for $2.8 billion.

Key Points: 
  • Notably, Exact Sciences purchased the Oncotype DX assay from Genomic Health for $2.8 billion.
  • The Company will hold a shareholders meeting on October 2, 2020 to vote on the planned demerger.
  • Accustem Sciences intends to list on the London Stock Exchange (LSE) in late Q4 2020, and potentially a dual listing on NASDAQ in 2021.
  • Gabriele Cerrone, Chairman of Tiziana, commented: We are extremely pleased to announce the planned spin out of our StemPrintER technology.